Unknown PHASE2 INTERVENTIONAL 2-arm NCT03105310

Pegylated Interferon Alone or in Combination With Ezetimibe for Patients With Chronic Hepatitis D

Sponsor: Aga Khan University

Interventions Ezetimibe Pegylated interferon alfa

Updated 6 times since 2017 Last updated: Apr 3, 2017 Started: Jan 31, 2016 Primary completion: Dec 31, 2016 Completion: Jun 30, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Hepatitis D, Chronic, this trial is ongoing. The trial is conducted by Aga Khan University and has accumulated 6 data snapshots since 2016. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Apr 2019 — Jan 2021 [monthly]

Unknown Status PHASE2

Status: Active Not Recruiting → Unknown Status
Jun 2018 — Apr 2019 [monthly]

Active Not Recruiting PHASE2

▶ Show 1 earlier version

May 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE2

First recorded

Jan 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Aga Khan University

Data source: Aga Khan University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.